Gene Therapy for Ophthalmic Disorders Summit on September 10-12, 2024 in Boston, United States

Ophthalmic drug developers are unlocking the full potential of gene therapy. Crucial lessons learnt from both clinical successes and failures, coupled with recent improvements in development and delivery, means that the space is poised to capitalize on the significant potential of the eye as a target for genetic medicine approaches.

Join 100+ industry leaders at the 5th Gene Therapy for Ophthalmic Disorders Summit to uncover cutting-edge gene therapy breakthroughs. Harness the latest developments in vector engineering to target retinal cells more effectively with higher transduction efficiency. Understand the crucial role of endpoint selection to clearly demonstrate product efficacy to the FDA AND EMA. Understand the risk-benefit profiles of different ocular administration routes including intravitreal, subretinal, and suprachoroidal delivery to choose the best option for your specific indication. Learn from successful clinical trials as well as where trials have fallen short of expectations to take forward crucial lessons learnt on progressing a gene therapy rapidly through the clinic without compromising on safety.

URLs:

Brochure: https://go.evvnt.com/2478440-2?pid=10008

Tickets: https://go.evvnt.com/2478440-3?pid=10008

Time: 8:00 AM - 5:00 PM

Prices:

Conference Only - Drug Developer: USD 2999.00,

Conference Only - Solution Provider: USD 3699.00,

Conference Only - Academic: USD 2599.00,

Conference + Workshop Day - Drug Developer: USD 4197.00,

Conference + Workshop Day - Solution Provider: USD 5097.00,

Conference + Workshop Day - Academic: USD 3597.00

Speakers: Abraham Scaria, Chief Scientific Officer, Beacon Therapeutics, Adam Silverman, Vice President - Protein Sciences, Spotlight Therapeutics, Aniz Girach, Chief Medical Officer, Splice Bio, Arun Upadhyay, Chief Scientific Officer, Head of Research and Development, Ocugen, Christopher Chavez, Vice President, Research and Development, Visgenx Inc., Claire Gelfman, Chief Scientific Officer, Foundation Fighting Blindness, Emily Warner, Principal Scientist, Ikarovec, Eric Kelsic, Founder and Chief Executive Officer, Dyno Therapeutics, Hanen Khabou, Senior Scientist, SparingVision, Hemant Khanna, Vice President, Preclinical Ocular Research, Astellas, Jean Chang, Vice President, Clinical Operations, Nanoscope Therapeutics Inc., Kali Stasi, Senior Vice President, Clinical Development, Adverum, Kenji Fujita, Chief Medical Officer, Atsena Therapeutics, Maryam Moktarzadeh, Senior Director, Regulatory Strategy, REGENXBIO, Melissa Calton, Vice President, Early-Stage Product Development, 4D Molecular Therapeutics, Molly Johnson, Director, Data Science, Avista Therapeutics, Moshe Weinstein, Chief Executive Officer, Ophthalmics, Everads-Therapy, Paul Wille Director, Product Development Process Development, Abeona Therapeutics, Peter Francis, Chief Scientific and Medical Officer, Ray Therapeutics, Rob Collin, Chief Scientific Officer, Astherna BV, Sarah DiSalvatore, Vice President, Clinical Operations, Ascidian Therapeutics, Stephen Poor, Executive Director and Head of Global Program Clinical Ophthalmology, Novartis AG, Szilard Kiss, Chief Medical Officer and Co-Founder, BlueGen Therapeutics, Viral Kansara, Vice President, Preclinical Development, Clearside Biomedical, Zhongdong Shi, Executive Director and Head of Vector Research and Development Research and Development, Frontera Therapeutics